A new trial evaluated whether neoadjuvant use of the tumour vaccine GVAX plus cyclophosphamide with androgen deprivation therapy (ADT) would augment antitumour immunity. ADT alone led to increased CD8+ T cell infiltration but also increases in regulatory cell populations. The results suggest that ADT should be used with treatments targeting the recruitment and persistence of these regulatory populations.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Drake, C. G. et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 7, 239–249 (2005).
Morse, M. D. & McNeel, D. G. Prostate cancer patients treated with androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum. Immunol. 71, 496–504 (2010).
Morse, M. D. & McNeel, D. G. T cells localized to the androgen-deprived prostate are TH1 and TH17 biased. Prostate 72, 1239–1247 (2012).
Mercader, M. et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl Acad. Sci. USA 98, 14565–14570 (2001).
McNeel, D. G. et al. Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. Oncotarget 9, 25586–25596 (2018).
Hagihara, K. et al. Neoadjuvant sipuleucel-T induces both TH1 activation and immune regulation in localized prostate cancer. Oncoimmunology 8, e1486953 (2019).
Obradovic, A. Z. et al. T-cell infiltration and adaptive Treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-19-3372 (2020).
Sorrentino, C., Musiani, P., Pompa, P., Cipollone, G. & Di Carlo, E. Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory T lymphocytes and has no effect on disease-free survival in prostate cancer patients. Clin. Cancer Res. 17, 1571–1581 (2011).
Gamat, M. & McNeel, D. G. Androgen deprivation and immunotherapy for the treatment of prostate cancer. Endocr. Relat. Cancer 24, T297–T310 (2017).
Antonarakis, E. S. et al. Sequencing of sipuleucel-T and androgen deprivation therapy in men with hormone-sensitive biochemically recurrent prostate cancer: a phase II randomized trial. Clin. Cancer Res. 23, 2451–2459 (2017).
Acknowledgements
D.G.M. is supported by the National Institutes of Health NIH R01 CA219154.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.G.M. has ownership interest in (stocks and intellectual property), has received research support from and serves as consultant to Madison Vaccines, Inc. M.G.-H. declares no competing interests.
Rights and permissions
About this article
Cite this article
Gamat-Huber, M., McNeel, D.G. Androgen deprivation as a tumour-immunomodulating treatment. Nat Rev Urol 17, 371–372 (2020). https://doi.org/10.1038/s41585-020-0328-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-020-0328-6
